

Annamaria Colao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11816657/annamaria-colao-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

391
papers

25,669
citations

89
h-index

139
g-index

398
ext. papers

29,010
ext. citations

6
avg, IF

6.85
L-index

#	Paper	IF	Citations
391	Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition.. <i>International Journal of Obesity</i> , 2022 ,	5.5	8
390	Clinical Case 1 2022 , 271-279		
389	Dietary Recommendations for Post-COVID-19 Syndrome.. <i>Nutrients</i> , 2022 , 14,	6.7	3
388	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 791633	5.7	
387	Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 769744	5.7	1
386	Improving sleep disturbances in obesity by nutritional strategies: review of current evidence and practical guide. <i>International Journal of Food Sciences and Nutrition</i> , 2021 , 72, 579-591	3.7	6
385	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , 2021 , 111, 1066-1085	5.6	31
384	The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. <i>Obesity Reviews</i> , 2021 , 22, e13216	10.6	10
383	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. <i>Nutrients</i> , 2021 , 13,	6.7	13
382	Vitamin D in obesity and obesity-related diseases: an overview. <i>Minerva Endocrinology</i> , 2021 , 46, 177-192.	2.5	16
381	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. <i>Journal of Translational Medicine</i> , 2021 , 19, 324	8.5	3
380	Terapia dei prolattinomi: quando sospendere?. <i>L Endocrinologo</i> , 2021 , 22, 337-341	0	
379	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021 , 151, 36-40	5	0
378	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 654-656	18.1	13
377	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
376	Commentary: Obesity: The "Achilles heel" for COVID-19?. <i>Metabolism: Clinical and Experimental</i> , 2020 , 108, 154251	12.7	120
375	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , 2020 , 12,	6.7	5

374	The Sun's Vitamin in Adult Patients Affected by Prader-Willi Syndrome. <i>Nutrients</i> , 2020 , 12,	6.7	4
373	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. <i>European Journal of Endocrinology</i> , 2020 , 182, 583	6.5	15
372	Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020 , 60, 912-918	1.4	2
371	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <i>Minerva Endocrinologica</i> , 2020 , 45, 127-137	1.9	12
370	Is obesity the missing link between COVID-19 severity and air pollution?. <i>Environmental Pollution</i> , 2020 , 266, 115327	9.3	7
369	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020 , 11, 648	5.7	23
368	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. <i>Critical Reviews in Food Science and Nutrition</i> , 2020 , 1-17	11.5	14
367	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	88
366	Nutritional recommendations for CoVID-19 quarantine. <i>European Journal of Clinical Nutrition</i> , 2020 , 74, 850-851	5.2	212
365	Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?. <i>Nutrients</i> , 2019 , 11,	6.7	16
364	VENUS BY BOTTICELLI AND HER PITUITARY ADENOMA. <i>Endocrine Practice</i> , 2019 , 25, 1067-1073	3.2	0
363	Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2019 , 10, 327	5.7	19
362	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 20	51.1	128
361	Dopamine Agonists: From the 1970s to Today. <i>Neuroendocrinology</i> , 2019 , 109, 34-41	5.6	6
360	Gut microbiota: a new path to treat obesity. <i>International Journal of Obesity Supplements</i> , 2019 , 9, 10-19	13.3	114
359	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence". <i>Endocrine</i> , 2019 , 64, 657-672	4	20
358	Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. <i>Frontiers in Endocrinology</i> , 2019 , 10, 931	5.7	9
357	Phase Angle: A Possible Biomarker to Quantify Inflammation in Subjects with Obesity and 25(OH)D Deficiency. <i>Nutrients</i> , 2019 , 11,	6.7	25

356	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019 , 127, 695-709	2.1	9
355	Acromegaly and Heart Failure. <i>Heart Failure Clinics</i> , 2019 , 15, 399-408	3.3	11
354	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2019 , 17, 610-617	3.3	15
353	Long-Term Complications of Hypercortisolism 2019 , 341-359		1
352	The management of neuroendocrine tumours: A nutritional viewpoint. <i>Critical Reviews in Food Science and Nutrition</i> , 2019 , 59, 1046-1057	11.5	26
351	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 325-374	0.1	
350	The effects of hyperprolactinemia and its control on metabolic diseases. <i>Expert Review of Endocrinology and Metabolism</i> , 2018 , 13, 99-106	4.1	12
349	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 1-50	0.1	
348	Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. <i>Archives of Toxicology</i> , 2018 , 92, 1831-1845	5.8	32
347	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018 , 62, 663-680	4	7
346	ACTH-Secreting Pituitary Tumors 2018 , 248-260		
345	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. <i>Cancer Treatment Reviews</i> , 2018 , 67, 1-9	14.4	21
344	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. <i>Endocrine</i> , 2018 , 60, 65-72	4	4
343	Nutrition, inflammation and liver-spleen axis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018 , 58, 3141-3158	11.5	38
342	Influence of nutrition on somatotrophic axis: Milk consumption in adult individuals with moderate-severe obesity. <i>Clinical Nutrition</i> , 2017 , 36, 293-301	5.9	31
341	The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. <i>Endocrine</i> , 2017 , 55, 564-572	4	24
340	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017 , 55, 872-884	4	28
339	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2017 , 56, 10-18	4	107

338	Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. <i>Neurosurgical Review</i> , 2017 , 40, 105-114	3.9	46
337	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017 , 20, 46-62	4.3	116
336	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 195-205	10.5	105
335	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017 , 176, 453-461	6.5	39
334	Male Hypogonadism Due to Disorders of the Pituitary and Suprasellar Region 2017 , 169-186		1
333	Cardiovascular alterations in adult GH deficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 25-34	6.5	24
332	Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly. <i>Pituitary</i> , 2017 , 20, 668-675	4.3	15
331	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. <i>Endocrine-Related Cancer</i> , 2017 , 24, 505-518	5.7	110
330	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017 , 24, 495-504	5.7	41
329	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2017 , 57, 314-325	4	14
328	Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 73-85	4.1	6
327	Six controversial issues on subclinical Cushing's syndrome. <i>Endocrine</i> , 2017 , 56, 262-266	4	29
326	Vitamin D and chronic diseases: the current state of the art. <i>Archives of Toxicology</i> , 2017 , 91, 97-107	5.8	78
325	Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 207-214	10.5	43
324	Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 930-932	18.1	0
323	The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. <i>Pituitary</i> , 2016 , 19, 210-21	4.3	53
322	Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016 , 207, 214-219	2.4	69
321	Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. <i>Pituitary</i> , 2016 , 19, 235-47	4.3	72

320	Cardiovascular risk in adult hypopituitary patients with growth hormone deficiency: is there a role for vitamin D?. <i>Endocrine</i> , 2016 , 52, 111-9	4	39
319	Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. <i>BMC Endocrine Disorders</i> , 2016 , 16, 16	3.3	48
318	The safety of treatments for prolactinomas. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 503-12	4.1	16
317	Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. <i>Endocrine</i> , 2016 , 53, 210-9	4	48
316	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, L43-4	5.6	2
315	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016 , 46, 54-65	3.5	22
314	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 611-29	18.1	229
313	Differential diagnosis and management of abnormal uterine bleeding due to hyperprolactinemia. <i>Middle East Fertility Society Journal</i> , 2016 , 21, 137-147	1.4	2
312	Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. <i>Journal of Translational Medicine</i> , 2016 , 14, 130	8.5	39
311	Hypovitaminosis D in adolescents living in the land of sun is correlated with incorrect life style: a survey study in Campania region. <i>Endocrine</i> , 2015 , 49, 521-7	4	10
310	Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. <i>Pituitary</i> , 2015 , 18, 385-94	4.3	50
309	Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index. <i>Endocrine</i> , 2015 , 49, 492-502	4	13
308	The Treatment of Cushing's Disease. <i>Endocrine Reviews</i> , 2015 , 36, 385-486	27.2	262
307	Adverse events associated with somatostatin analogs in acromegaly. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1213-26	4.1	25
306	Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. <i>Neuroendocrinology</i> , 2015 , 101, 66-81	5.6	19
305	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015 , 50, 725-40	4	36
304	Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. <i>Journal of Translational Medicine</i> , 2015 , 13, 18	8.5	83
303	The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. <i>Journal of Hypertension</i> , 2015 , 33, 44-60	1.9	92

302	Cabergoline use for pituitary tumors and valvular disorders. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015 , 44, 89-97	5.5	28
301	Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. <i>Endocrine Journal</i> , 2015 , 62, 1037-48	2.9	26
300	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. <i>Journal of Translational Medicine</i> , 2015 , 13, 303	8.5	46
299	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015 , 9, 129	5.1	86
298	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. <i>Growth Hormone and IGF Research</i> , 2015 , 25, 28-33	2	25
297	Efficacy and tolerability of treatment with pegvisomant in acromegaly: an overview of literature. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 97-108	1.1	1
296	Hypothalamic Growth Hormone/IGF-1 Axis 2015 , 53-62		
295	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , 2014 , 47, 9-20	4	52
294	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 99-112	5.2	24
293	Second attempt to withdraw cabergoline in prolactinomas: a pilot study. <i>Pituitary</i> , 2014 , 17, 451-6	4.3	18
292	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 875-84	18.1	233
291	Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2942-51	5.6	48
290	Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. <i>Scientific World Journal, The</i> , 2014 , 2014, 282147	2.2	38
289	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014 , 170, 311-9	6.5	45
288	The complex relationship between obesity and the somatotropic axis: the long and winding road. <i>Growth Hormone and IGF Research</i> , 2014 , 24, 221-6	2	54
287	How should patients with adrenal incidentalomas be followed up?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 352-4	18.1	1
286	Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. <i>Pituitary</i> , 2014 , 17, 180-6	4.3	102
285	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014 , 46, 181-98	4	27

284	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , 2014 , 4, 329-329		8
283	Investigational therapies for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 955-63	5.9	12
282	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 557-567	1.1	2
281	The circulating level of FABP3 is an indirect biomarker of microRNA-1. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 88-95	15.1	45
280	Cardiovascular involvement in patients affected by acromegaly: an appraisal. <i>International Journal of Cardiology</i> , 2013 , 167, 1712-8	3.2	65
279	Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. <i>Clinical Endocrinology</i> , 2013 , 78, 447-53	3.4	65
278	Medical Management of Pituitary Adenomas 2013 , 225-242		
277	Complications of Pituitary Disease 2013 , 277-290		
276	Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. <i>European Journal of Endocrinology</i> , 2013 , 169, 359-66	6.5	54
275	Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. <i>European Journal of Endocrinology</i> , 2013 , 168, 15-22	6.5	23
274	Effect of cabergoline on metabolism in prolactinomas. <i>Neuroendocrinology</i> , 2013 , 98, 299-310	5.6	42
273	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , 2013 , 79, 211-6	3.4	7
272	Hereditary Neuroendocrine Tumor Syndromes 2013 ,		2
271	Quality of life in patients with Cushing's disease: a modern approach. <i>Clinical Endocrinology</i> , 2012 , 76, 776-7	3.4	10
270	Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. <i>Pituitary</i> , 2012 , 15, 50-8	4.3	37
269	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2012 , 15, 539-51	4.3	26
268	Iperprolattinemia, farmaci dopaminergici e valvulopatie: vero o falso?. <i>L Endocrinologo</i> , 2012 , 13, 127-131		
267	Subclinical Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012 , 26, 497-505	6.5	47

266	Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. <i>Diabetes Care</i> , 2012 , 35, 2402-11	14.6	609
265	Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. <i>Drug Safety</i> , 2012 , 35, 159-71	5.1	37
264	Vitamin D and cancer. <i>Frontiers in Endocrinology</i> , 2012 , 3, 58	5.7	101
263	Endocrinologically Silent Pituitary Tumors 2012 , 246-256		2
262	A 12-month phase 3 study of pasireotide in Cushing's disease. <i>New England Journal of Medicine</i> , 2012 , 366, 914-24	59.2	448
261	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. <i>Endocrine-Related Cancer</i> , 2012 , 19, 149-55	5.7	61
260	Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2012 , 19, 288-94	4	13
259	Acromegaly and Changes in Growth Parameters: A Focus on Cardiovascular, Metabolic, Respiratory Abnormalities, Malignancies, and Bone Alterations 2012 , 2047-2066		
258	Medical treatment of prolactinomas. <i>Nature Reviews Endocrinology</i> , 2011 , 7, 267-78	15.2	112
257	Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. <i>Clinical Endocrinology</i> , 2011 , 74, 234-40	3.4	6
256	Aortic root ectasia in patients with acromegaly: an emerging complication. <i>Clinical Endocrinology</i> , 2011 , 75, 420-1	3.4	7
255	Aumento della rigidità arteriosa nei bambini affetti da sindrome di Cushing dopo guarigione chirurgica. <i>L'Endocrinologo</i> , 2011 , 12, 41-42	0	
254	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , 2011 , 165, 713-21	6.5	57
253	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. <i>European Journal of Endocrinology</i> , 2011 , 164, 341-7	6.5	34
252	Resistance to somatostatin analogs in acromegaly. <i>Endocrine Reviews</i> , 2011 , 32, 247-71	27.2	186
251	Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. <i>European Journal of Endocrinology</i> , 2011 , 164, 325-33	6.5	64
250	Therapy of aggressive pituitary tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1561-70	4	49
249	10. Perspectives in the Development of Novel Treatment Approaches. <i>Tumori</i> , 2010 , 96, 858-873	1.7	

248	Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 13-7	5.6	38
247	Growth hormone: health considerations beyond height gain. <i>Pediatrics</i> , 2010 , 125, e906-18	7.4	34
246	Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. <i>European Journal of Endocrinology</i> , 2010 , 162, 993-9	6.5	10
245	Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. <i>Diabetes Care</i> , 2010 , 33, 246-51	14.6	58
244	Pathophysiology of diabetes mellitus in Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 77-83	6	116
243	Pituitary carcinomas. <i>Frontiers of Hormone Research</i> , 2010 , 38, 94-108	3.5	28
242	Uso degli analoghi della somatostatina nei tumori neuroendocrini: indicazioni e limiti. <i>L'Endocrinologo</i> , 2010 , 11, 40-44	0	
241	Cardiovascular disease in Cushing's syndrome: heart versus vasculature. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 50-4	5.6	74
240	Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. <i>Progress in Brain Research</i> , 2010 , 182, 281-94	2.9	24
239	Prolactinomas in children and adolescents. <i>Endocrine Development</i> , 2010 , 17, 146-159		20
238	Relationship between growth hormone/insulin-like growth factor-1 axis integrity and voluntary weight loss after gastric banding surgery for severe obesity. <i>Obesity Surgery</i> , 2010 , 20, 211-20	3.7	17
237	The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. <i>Pituitary</i> , 2010 , 13, 266-86	4.3	7
236	Is arginine test a reliable tool for differential diagnosis of multiple system atrophy?. <i>Annals of Neurology</i> , 2010 , 68, 564-5; author reply 565-6	9.4	
235	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. <i>BMC Endocrine Disorders</i> , 2010 , 10, 10	3.3	39
234	Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. <i>World Journal of Gastroenterology</i> , 2010 , 16, 4773-83	5.6	130
233	A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4414-22	5.6	55
232	Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. <i>Thyroid</i> , 2009 , 19, 219-25	6.2	194
231	Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3347-55	5.6	30

230	Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 1541-7	5.6	227
229	Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2907-14	5.6	41
228	Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 528-37	5.6	47
227	Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 817-26	5.6	17
226	Androgens in polycystic ovary syndrome: the role of exercise and diet. <i>Seminars in Reproductive Medicine</i> , 2009 , 27, 306-15	1.4	27
225	Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3746-56	5.6	107
224	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , 2009 , 46, 85-95	3.9	95
223	Medical therapy of pituitary adenomas: effects on tumor shrinkage. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009 , 10, 111-23	10.5	43
222	Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study. <i>Journal of Ovarian Research</i> , 2009 , 2, 3	5.5	15
221	Inflammatory markers and visceral fat are inversely associated with maximal oxygen consumption in women with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2009 , 70, 394-400	3.4	20
220	Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. <i>Clinical Endocrinology</i> , 2009 , 70, 757-68	3.4	90
219	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009 , 71, 237-45	3.4	51
218	Pituitary tumours: the prolactinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23, 575-96	6.5	107
217	5 Long-term acromegaly and associated cardiovascular complications: a case-based review. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23 Suppl 1, S31-8	6.5	12
216	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 223-30	5.6	250
215	Visceral fat and cardiovascular risk in patients with polycystic ovary syndrome. <i>Clinical Lipidology</i> , 2009 , 4, 623-632		
214	Hepatic steatosis in overweight/obese females: new screening method for those at risk. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5693-9	5.6	12
213	Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. <i>Clinical Endocrinology</i> , 2008 , 68, 66-71	3.4	98

212	Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2008 , 68, 88-93	3-4	39
211	Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. <i>Clinical Endocrinology</i> , 2008 , 68, 976-81	3-4	35
210	GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding. <i>Clinical Endocrinology</i> , 2008 , 69, 393-9	3-4	21
209	GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. <i>Clinical Endocrinology</i> , 2008 , 69, 613-20	3-4	33
208	The GH-IGF-I axis and the cardiovascular system: clinical implications. <i>Clinical Endocrinology</i> , 2008 , 69, 347-58	3-4	154
207	Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. <i>Clinical Endocrinology</i> , 2008 , 69, 756-62	3-4	29
206	Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). <i>Clinical Endocrinology</i> , 2008 , 69, 792-8	3-4	68
205	Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. <i>Clinical Endocrinology</i> , 2008 , 69, 831-44	3-4	19
204	Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 135-49, ix	5-5	132
203	Complicanze cardiovascolari dell'acromegalia. <i>L'Endocrinologo</i> , 2008 , 9, 21-27	0	
202	Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. <i>European Journal of Endocrinology</i> , 2008 , 158, 19-25	6-5	40
201	Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. <i>European Journal of Endocrinology</i> , 2008 , 159, 389-97	6-5	80
200	Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3777-84	5-6	127
199	No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2243-8	5-6	23
198	Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 710-4	5-6	16
197	Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2639-46	5-6	64
196	Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1412-7	5-6	96
195	Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3416-24	5-6	50

194	Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3436-42	5.6	26
193	Medical therapy for clinically non-functioning pituitary adenomas. <i>Endocrine-Related Cancer</i> , 2008 , 15, 905-15	5.7	131
192	Cardiovascular risk in women with polycystic ovary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 987-92	1.9	52
191	Endoscopic pituitary surgery. <i>Pituitary</i> , 2008 , 11, 385-90	4.3	81
190	Quality of life in women with microprolactinoma treated with dopamine agonists. <i>Pituitary</i> , 2008 , 11, 247-54	4.3	36
189	Medical consequences of acromegaly: what are the effects of biochemical control?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2008 , 9, 21-31	10.5	28
188	US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. <i>Ultrasound in Medicine and Biology</i> , 2008 , 34, 784-91	3.5	147
187	Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2008 , 23, 153-9	5.7	110
186	When and How to Stop Cabergoline Treatment in Microprolactinomas 2008 , 19-25		
185	Terapia di prima linea dell'acromegalia. <i>L Endocrinologo</i> , 2007 , 8, 125-129	0	
184	Guías de la Pituitary Society para el diagnóstico y tratamiento de los prolactinomas. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2007 , 54, 438.e1-438.e10		
183	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007 , 51, 1381-91		59
182	Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. <i>Modern Pathology</i> , 2007 , 20, 1172-82	9.8	210
181	The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. <i>Clinical Endocrinology</i> , 2007 , 66, 251-7	3.4	83
180	Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. <i>Clinical Endocrinology</i> , 2007 , 66, 714-22	3.4	22
179	Lack of electrocardiographic changes in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2007 , 67, 46-50	3.4	2
178	Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. <i>Clinical Endocrinology</i> , 2007 , 67, 426-33	3.4	77
177	Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2007 , 67, 557-62	3.4	6

176	Body fat in nonobese women with prolactinoma treated with dopamine agonists. <i>Clinical Endocrinology</i> , 2007 , 67, 845-52	3.4	33
175	Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. <i>Journal of the American Geriatrics Society</i> , 2007 , 55, 1478-9	5.6	45
174	Antipituitary antibodies in idiopathic hyperprolactinemic patients. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1107, 129-35	6.5	25
173	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S13-S21	6.5	90
172	Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. <i>European Journal of Endocrinology</i> , 2007 , 157, 359-66	6.5	51
171	The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3854-60	5.6	47
170	Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S57-S63	6.5	34
169	Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4536-45	5.6	56
168	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 65-9	5.6	58
167	Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 476-82	5.6	59
166	SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. <i>Clinical Cancer Research</i> , 2007 , 13, 2738-44	12.9	34
165	Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. <i>European Journal of Endocrinology</i> , 2007 , 157, 69-73	6.5	37
164	Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2007 , 157, 579-87	6.5	65
163	Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S37-S43	6.5	18
162	Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1379-84	5.6	136
161	Cardiopulmonary impairment in young women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2967-71	5.6	55
160	Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1779-84	5.6	90
159	Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4395-400	5.6	82

158	The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2191-200	5.6	34
157	Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1288-95	5.6	53
156	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , 2006 , 154, 467-77	6.5	133
155	Advances in the treatment of prolactinomas. <i>Endocrine Reviews</i> , 2006 , 27, 485-534	27.2	564
154	Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2112-8	5.6	104
153	Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 200-10		46
152	Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 85-92	5.6	146
151	Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2006 , 21, 457-65	5.7	68
150	Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study. <i>Human Reproduction</i> , 2006 , 21, 2823-9	5.7	47
149	Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age. <i>Gynecological Endocrinology</i> , 2006 , 22, 329-35	2.4	13
148	Acromegaly and the cardiovascular system. <i>Neuroendocrinology</i> , 2006 , 83, 211-7	5.6	73
147	Cardiovascular risk in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2006 , 86 Suppl 1, S20-1	4.8	48
146	Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. <i>Growth Hormone and IGF Research</i> , 2006 , 16 Suppl A, S41-8	2	69
145	The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. <i>Clinical Endocrinology</i> , 2006 , 64, 307-13	3.4	39
144	First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. <i>Clinical Endocrinology</i> , 2006 , 64, 342-51	3.4	63
143	Pulsed tissue Doppler identifies subclinical myocardial biventricular dysfunction in active acromegaly. <i>Clinical Endocrinology</i> , 2006 , 64, 390-7	3.4	11
142	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. <i>Clinical Endocrinology</i> , 2006 , 65, 265-73	3.4	558
141	Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. <i>Clinical Endocrinology</i> , 2006 , 65, 250-6	3.4	38

140	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. <i>Clinical Endocrinology</i> , 2006 , 65, 536-43	3.4	118
139	The metabolic syndrome and cardiovascular risk in Cushing's syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 327-39, viii	5.5	117
138	The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2-5	5.6	169
137	Endocrine disorders during the first year after autologous stem-cell transplant. <i>American Journal of Medicine</i> , 2005 , 118, 664-70	2.4	34
136	Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4068-74	5.6	211
135	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. <i>Clinical Endocrinology</i> , 2005 , 63, 342-9	3.4	24
134	Hypertension in acromegaly and in the normal population: prevalence and determinants. <i>Clinical Endocrinology</i> , 2005 , 63, 470-6	3.4	87
133	Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2005 , 63, 631-5	3.4	28
132	PRL secreting adenomas in male patients. <i>Pituitary</i> , 2005 , 8, 39-42	4.3	48
131	Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6072-6	5.6	116
130	Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2659-65	5.6	32
129	Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2056-62	5.6	48
128	Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5146-55	5.6	40
127	Cabergoline plus lanreotide for ectopic Cushing's syndrome. <i>New England Journal of Medicine</i> , 2005 , 352, 2457-8	59.2	68
126	Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 84-90	5.6	85
125	Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6616-22	5.6	29
124	The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. <i>European Journal of Endocrinology</i> , 2005 , 153, 257-64	6.5	265
123	Somatostatin Analogs in the Treatment of Pituitary Tumors 2004 , 215-231		

122	Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4493-502	5.6	63
121	Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4801-9	5.6	146
120	The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5998-6004	5.6	91
119	Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 621-5	5.6	68
118	Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2770-5	5.6	19
117	Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4588-93	5.6	273
116	Dopamine receptor expression and function in corticotroph pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2452-62	5.6	210
115	Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5110-5	5.6	49
114	Acromegalic axial arthropathy: a clinical case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 598-603	5.6	55
113	Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1674-83	5.6	97
112	Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. <i>Clinical Endocrinology</i> , 2004 , 60, 343-9	3.4	20
111	Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. <i>Clinical Endocrinology</i> , 2004 , 60, 630-6	3.4	48
110	Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2004 , 61, 360-6 ^{3.4}		43
109	Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1704-11	5.6	156
108	Systemic complications of acromegaly: epidemiology, pathogenesis, and management. <i>Endocrine Reviews</i> , 2004 , 25, 102-52	27.2	880
107	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. <i>Reproductive BioMedicine Online</i> , 2004 , 9, 505-10	4	55
106	The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3696-701	5.6	217
105	Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004 , 3, 309-18		26

104	Cardiovascular effects of growth hormone treatment: potential risks and benefits. <i>Hormone Research in Paediatrics</i> , 2004 , 62 Suppl 3, 42-50	3.3	7
103	High serum leptin in patients with chronic graft-versus-host disease after hematopoietic stem cell transplantation. <i>Transplantation</i> , 2004 , 78, 1376-83	1.8	18
102	Male Hypogonadism Resulting From Disorders of the Pituitary and Suprasellar Region 2004 , 139-158		
101	Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5258-65	5.6	62
100	Circulating ghrelin concentrations in the polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 942-5	5.6	69
99	Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2076-80	5.6	69
98	Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4105-9	5.6	10
97	Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 673-9	5.6	72
96	Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2527-33	5.6	264
95	Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 88-94	5.6	22
94	Adiponectin levels in women with polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2619-23	5.6	133
93	When can we stop cabergoline treatment in prolactinomas?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2003 , 10, 259-264		3
92	Hyperprolactinemia in men: clinical and biochemical features and response to treatment. <i>Endocrine</i> , 2003 , 20, 75-82		75
91	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003 , 58, 169-76	3.4	87
90	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , 2003 , 58, 302-8	3.4	82
89	Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. <i>New England Journal of Medicine</i> , 2003 , 349, 2023-33	59.2	255
88	Ultrasound-guided laser thermal ablation in the treatment of autonomous hyperfunctioning thyroid nodules and compressive nontoxic nodular goiter. <i>Thyroid</i> , 2003 , 13, 941-7	6.2	105
87	High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3196-201	5.6	98

86	Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5887-92	5.6	88
85	Influence of growth hormone on cardiovascular health and disease. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003 , 2, 347-56		4
84	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2003 , 148, 325-31	6.5	158
83	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. <i>European Journal of Endocrinology</i> , 2003 , 148, 31-8	6.5	42
82	Pregnancy outcome after cabergoline treatment in early weeks of gestation. <i>Reproductive Toxicology</i> , 2002 , 16, 791-3	3.4	121
81	High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. <i>Cancer</i> , 2002 , 95, 1076-84	6.4	132
80	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , 2002 , 56, 153-8	3.4	62
79	(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , 2002 , 56, 713-21	3.4	6
78	Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. <i>Journal of Neurosurgery</i> , 2002 , 97, 293-8	3.2	355
77	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2002 , 146, 303-9	6.5	57
76	The cardiovascular risk of GH-deficient adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3650-5	5.6	96
75	Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1502-8	5.6	45
74	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 787-800	5.9	90
73	Early vascular alterations in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3174-8	5.9	91
72	The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1088-93	5.6	86
71	Cardiovascular consequences of early-onset growth hormone excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3097-104	5.6	74
70	Acromegaly and immune function. <i>NeuroImmune Biology</i> , 2002 , 247-257		1
69	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 125-8	5.2	19

68	Trattamento a lungo termine dell'acromegalia mediante pegvisomant, un antagonista del recettore dell'ormone della crescita. <i>L Endocrinologo</i> , 2002 , 3, 250-252	0	
67	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , 2001 , 54, 469-77	3.4	22
66	Growth hormone and the heart. <i>Clinical Endocrinology</i> , 2001 , 54, 137-54	3.4	276
65	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001 , 54, 515-24	3.4	84
64	Are patients with acromegaly at high risk for dysrhythmias?. <i>Clinical Endocrinology</i> , 2001 , 55, 305-6	3.4	20
63	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , 2001 , 4, 251-7	4.3	22
62	Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2779-86	5.6	213
61	Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5256-61	5.6	169
60	Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 3001-8	5.6	80
59	Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1874-81	5.6	105
58	Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1551-7	5.6	94
57	Trattamento dell'acromegalia: attualità e prospettive. <i>L Endocrinologo</i> , 2001 , 2, 99-109	0	
56	Physiological Effects of Growth Hormone on the Heart. <i>Growth Hormone</i> , 2001 , 13-22		
55	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000 , 52, 319-27	3.4	76
54	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with ¹²³ I-methoxybenzamide. <i>Clinical Endocrinology</i> , 2000 , 52, 437-45	3.4	40
53	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. <i>Clinical Endocrinology</i> , 2000 , 52, 447-55	3.4	28
52	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000 , 53, 53-60	3.4	60
51	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000 , 53, 13-9	3.4	43

50	Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 193-9	5.6	137
49	Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3720-5	5.6	56
48	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2247-52	5.6	146
47	Cardiac effect of thyrotoxicosis in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1426-32	5.6	15
46	Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3754-61	5.6	34
45	Muscle sympathetic nerve activity in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3203-7	5.6	14
44	Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 4099-103	5.6	89
43	Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3132-40	5.6	85
42	New medical approaches in pituitary adenomas. <i>Hormone Research in Paediatrics</i> , 2000 , 53 Suppl 3, 76-87.3		29
41	Acromegaly and prostate cancer. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S37-8	2	7
40	Cabergoline. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 555-74	4	55
39	Pharmacotherapy or surgery as primary treatment for acromegaly?. <i>Drugs and Aging</i> , 2000 , 17, 81-92	4.7	26
38	Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1518-23	5.6	61
37	Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1919-24	5.6	138
36	Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. <i>Skull Base</i> , 1999 , 9, 109-17		77
35	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2664-72	5.6	291
34	In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. <i>Endocrinology</i> , 1999 , 140, 373-80	4.8	82
33	Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 17-23	5.6	101

32	Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2349-52	5.6	9
31	Impaired cardiac performance in elderly patients with growth hormone deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3950-5	5.6	67
30	The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1277-82	5.6	80
29	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1986-91	5.6	58
28	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , 1999 , 51, 611-8	3.4	51
27	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999 , 1, 115-20	4.3	69
26	Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors. <i>Pituitary</i> , 1998 , 1, 59-67	4.3	12
25	Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. <i>Clinical Endocrinology</i> , 1998 , 48, 137-43	3.4	98
24	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 48, 655-62	3.4	56
23	Growth-hormone and prolactin excess. <i>Lancet, The</i> , 1998 , 352, 1455-61	4.0	212
22	Treatment of prolactinomas. <i>Annals of Medicine</i> , 1998 , 30, 452-9	1.5	57
21	Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2777-80	5.6	137
20	Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 807-13	5.6	92
19	Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 248-52	5.6	32
18	Reversibility of joint thickening in acromegalic patients: an ultrasonography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2121-5	5.6	60
17	Prostatic hyperplasia: an unknown feature of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 775-9	5.6	86
16	Effect of different dopaminergic agents in the treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 518-23	5.6	121
15	Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3574-9	5.6	127

14	Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2756	5.6	11
13	Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 876-83	5.6	189
12	Effect of octreotide pretreatment on surgical outcome in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3308-14	5.6	184
11	Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2777-81	5.6	113
10	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997 , 47, 23-8	3.4	77
9	Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. <i>European Journal of Endocrinology</i> , 1996 , 135, 548-52	6.5	33
8	Cardiovascular aspects in acromegaly: effects of treatment. <i>Metabolism: Clinical and Experimental</i> , 1996 , 45, 57-60	12.7	32
7	Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 390-4		64
6	Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. <i>Hormone Research</i> , 1995 , 44, 222-8		19
5	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , 1995 , 132, 559-64	6.5	31
4	Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. <i>Hormone Research</i> , 1993 , 40, 149-55		27
3	Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). <i>Clinical Endocrinology</i> , 1990 , 33, 161-9	3.4	32
2	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus		5
1	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine Abstracts</i> ,		2